Table 1 Demographic characteristics of individuals experiencing adverse events (AEs) reported as a suspected drug of Rifampin or Isoniazid to the Korea adverse event reporting system (KAERS) between 2017 and 2021.
Characteristics | Rifampin | Isoniazid | ||||
|---|---|---|---|---|---|---|
Active TB (N = 3560) | Latent TB (N = 262) | Others (N = 1239) | Active TB (N = 51) | Latent TB (N = 2) | Others(N = 18) | |
Sex-no. (%) | ||||||
Male | 1,920 (53.93) | 86 (32.82) | 508 (41) | 34 (66.67) | 1 (50) | 9 (50) |
Female | 1,640 (46.07) | 176 (67.18) | 731 (59) | 17 (33.33) | 1 (50) | 9 (50) |
Age group-no.(%) | ||||||
< 24 months | 1 (0.03) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
24 months − 11 yrs | 2 (0.06) | 3 (1.15) | 4 (0.32) | 0 (0) | 0 (0) | 0 (0) |
12–18 yrs | 31 (0.87) | 22 (8.4) | 15 (1.21) | 0 (0) | 0 (0) | 0 (0) |
19–29 yrs | 276 (7.75) | 40 (15.27) | 53 (4.28) | 3 (5.88) | 0 (0) | 5 (27.78) |
30–39 yrs | 364 (10.22) | 32 (12.21) | 76 (6.13) | 10 (19.61) | 0 (0) | 3 (16.67) |
40–49 yrs | 458 (12.87) | 48 (18.32) | 163 (13.16) | 7 (13.73) | 2 (100) | 0 (0) |
50–59 yrs | 634 (17.81) | 84 (32.06) | 279 (22.52) | 18 (35.29) | 0 (0) | 2 (11.11) |
60–64 yrs | 340 (9.55) | 18 (6.87) | 154 (12.43) | 4 (7.84) | 0 (0) | 1 (5.56) |
≥ 65 yrs | 1,454 (40.84) | 15 (5.73) | 495 (39.95) | 9 (17.65) | 0 (0) | 7 (38.89) |
Type of reporter-no.(%) | ||||||
Medical professionals | 3497(99.74) | 256(97.71) | 1175(94.83) | 49(96.08) | 2(100) | 17(94.44) |
Others (Consumer, lawyer, unknown.) | 63(1.77%) | 6(2.29%) | 64(5.17%) | 2(3.91%) | 0 (0) | 1(5.56%) |
Source of report- no.(%) | ||||||
Regional pharmacovigilance center | 2,798 (78.6) | 186 (70.99) | 914 (73.77) | 10 (19.61) | 2 (100) | 4 (22.22) |
Medical professionals | 709 (19.92) | 74 (28.24) | 305 (24.62) | 2 (3.92) | 0 (0) | 13 (72.22) |
Manufacture | 31 (0.87) | 0 (0) | 6 (0.48) | 39 (76.47) | 0 (0) | 0 (0) |
Patients/Consumers | 1 (0.03) | 0 (0) | 4 (0.32) | 0 (0) | 0 (0) | 1 (5.56) |
Others | 21 (0.59) | 2 (0.76) | 10 (0.81) | 0 (0) | 0 (0) | 0 (0) |
Report type-no.(%) | ||||||
Spontaneous reports | 3,530 (99.16) | 262 (100) | 1,236 (99.76) | 13 (25.49) | 2 (100) | 18 (100) |
Reports from Trial/Research | 29 (0.81) | 0 (0) | 0 (0) | 36 (70.59) | 0 (0) | 0 (0) |
Others | 1 (0.03) | 0 (0) | 3 (0.24) | 2 (3.92) | 0 (0) | 0 (0) |
